Press Releases

September 27, 2018

Allogene Therapeutics Appoints Deborah M. Messemer, Former KPMG Managing Partner, to its Board of Directors

September 14, 2018

Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

September 6, 2018

Allogene Therapeutics Completes a $120 Million Private Financing

August 28, 2018

Allogene Therapeutics Appoints David M. Tillett, Ph.D., as Senior Vice President, Head of Quality

August 14, 2018

Allogene Therapeutics Appoints Susie Jun, M.D., Ph.D., as Chief Development Officer

July 10, 2018

Allogene Therapeutics Announces Scientific Advisory Board

June 18, 2018

Allogene Therapeutics Announces Eric T. Schmidt, Ph.D. as Chief Financial Officer

June 12, 2018

Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports

June 4, 2018

Allogene Therapeutics Appoints Alison Moore, Ph.D. as Chief Technical Officer

May 30, 2018

Allogene Therapeutics Announces Board of Directors

May 14, 2018

Allogene Therapeutics Announces Poster Presentation at the Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

April 9, 2018

Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-­oncology Portfolio

April 3, 2018

Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies

April 3, 2018

Pfizer and Allogene Therapeutics Enter Into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio